Albendazole in the Treatment of Onchocerciasis: Double-Blind Clinical Trial in Venezuela

Bl, Cline; Jl, Hernández; Fj, Mather; Bartholomew, R.A.; Sn, De Maza; Rodulfo, S; Ca, Welborn; Ml, Eberhard; Convit, J

doi:10.4269/ajtmh.1992.47.512

Cited by 24 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The additive or synergistic effect of this benzimidazole, if any, when used in combination with other anthelminthics for the treatment of lymphatic filariasis remains controversial, particularly with regard to macrofilaricidal efficacy [ 37 - 40 ]. Certainly, albendazole had no significant micro- or macrofilaricidal activity in clinical trials for human onchocerciasis conducted in the early 1990s, although it induced embryotoxic effects in female worms [ 41 , 42 ]. Whether the more demonstrable macrofilaricidal efficacy of UMF-078 is an intrinsic characteristic of the drug ( e.g .…”

Section: Discussionmentioning

confidence: 99%

UMF-078: A modified flubendazole with potent macrofilaricidal activity against Onchocerca ochengi in African cattle

et al. 2008

View full text Add to dashboard Cite

Background: Human onchocerciasis or river blindness, caused by the filarial nematode Onchocerca volvulus, is currently controlled using the microfilaricidal drug, ivermectin. However, ivermectin does not kill adult O. volvulus, and in areas with less than 65% ivermectin coverage of the population, there is no effect on transmission. Therefore, there is still a need for a macrofilaricidal drug. Using the bovine filarial nematode O. ochengi (found naturally in African cattle), the macrofilaricidal efficacy of the modified flubendazole, UMF-078, was investigated.

show abstract

Section: Discussionmentioning

confidence: 99%

UMF-078: A modified flubendazole with potent macrofilaricidal activity against Onchocerca ochengi in African cattle

et al. 2008

View full text Add to dashboard Cite

show abstract

“…After treatment with diethylcarbamazine (DEC), Onchocerca volvulus mf migrate to the blood, the urine, and the cerebrospinal fluid (CSF). 8,9 The passage of O. volvulus mf into the blood and/or the urine has also been reported after treatment with albendazole 10 and ivermectin. [11][12][13] The presence of L. loa mf in the CSF of patients who have developed a SAE after DEC treatment 14 and the fact that L. loa mf were found in the brain parenchyma in one of these cases 15 may indicate that DEC induces a migration of Loa mf in the CNS.…”

Section: Introductionmentioning

confidence: 99%

Loa loa Microfilarial Periodicity in Ivermectin-Treated Patients: Comparison Between Those Developing and Those Free of Serious Adverse Events

Kamgno¹,

Pion²,

Mackenzie³

et al. 2009

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. The main risk factor of post-ivermectin serious adverse events (SAEs) is the presence of a high Loa loa microfilaremia. However, the majority of patients with such high loads do not develop SAEs, suggesting that co-factors may be involved. An infection with simian Loa parasites, whose microfilariae show a nocturnal periodicity, might be such a co-factor. The periodicity of Loa microfilariae was compared, using cosinor methodology, in 4 patients who had developed a post-ivermectin neurologic SAE, 4 patients who had experienced a non-neurologic SAE, and 14 control individuals. The periodicity was similar in all three groups, with a peak of microfilaremia occurring between 12:30 and 2:00 pm . The results of this study, which for the first time characterizes the periodicity of Loa microfilariae mathematically, suggest that post-ivermectin SAEs are not related to an infection with a Loa simian strain.

show abstract

“…The rationale for the addition of albendazole to ivermectin is based on the results of prior clinical studies. These suggested an effect of albendazole on adult worm fertility (Cline et al., 1992, Awadzi et al., 1995, Awadzi et al., 2003) which might be larger with higher and repeated albendazole doses.…”

Section: Research For New Drugs For Onchocerciasis Control and Eliminmentioning

confidence: 99%

Research for new drugs for elimination of onchocerciasis in Africa

Kuesel

2016

International Journal for Parasitology: Drugs and Drug Resistan

View full text Add to dashboard Cite

Onchocerciasis is a parasitic, vector borne disease caused by the filarial nematode Onchocerca volvulus. More than 99% of the population at risk of infection live in Africa. Onchocerciasis control was initiated in West Africa in 1974 with vector control, later complemented by ivermectin mass drug administration and in the other African endemic countries in 1995 with annual community directed treatment with ivermectin (CDTI.) This has significantly reduced infection prevalence. Together with proof-of-concept for onchocerciasis elimination with annual CDTI from foci in Senegal and Mali, this has resulted in targeting onchocerciasis elimination in selected African countries by 2020 and in 80% of African countries by 2025. The challenges for meeting these targets include the number of endemic countries where conflict has delayed or interrupted control programmes, cross-border foci, potential emergence of parasite strains with low susceptibility to ivermectin and co-endemicity of loiasis, another parasitic vector borne disease, which slows down or prohibits CDTI implementation. Some of these challenges could be addressed with new drugs or drug combinations with a higher effect on Onchocerca volvulus than ivermectin. This paper reviews the path from discovery of new compounds to their qualification for large scale use and the support regulatory authorities provide for development of drugs for neglected tropical diseases. The status of research for new drugs or treatment regimens for onchocerciasis along the path to regulatory approval and qualification for large scale use is reviewed. This research includes new regimens and combinations of ivermectin and albendazole, antibiotics targeting the O. volvulus endosymbiont Wolbachia, flubendazole, moxidectin and emodepside and discovery of new compounds.

show abstract

Albendazole in the Treatment of Onchocerciasis: Double-Blind Clinical Trial in Venezuela

Cited by 24 publications

References 0 publications

UMF-078: A modified flubendazole with potent macrofilaricidal activity against Onchocerca ochengi in African cattle

UMF-078: A modified flubendazole with potent macrofilaricidal activity against Onchocerca ochengi in African cattle

Loa loa Microfilarial Periodicity in Ivermectin-Treated Patients: Comparison Between Those Developing and Those Free of Serious Adverse Events

Research for new drugs for elimination of onchocerciasis in Africa

Contact Info

Product

Resources

About